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Original article
Purpose: This study aimed to investigate associations of central obesity with sexual 
maturation and metabolic parameters in Korean girls with precocious puberty. 
Methods: This retrospective study evaluated data from 72 girls under 8 years of age 
with a chief complaint of early breast development. The patients were categorized 
as central precocious puberty (CPP) subjects or non-CPP subjects based on their 
gonadotropin-releasing hormone stimulation test results. Visceral fat thickness (VFT) 
was measured using ultrasonography and defined as the distance from the linea 
alba to the aorta. Patient anthropometric, metabolic, and hormonal parameters 
were also evaluated.
Results: Increased VFT was correlated with an earlier onset of thelarche among all 
study subjects (r=-0.307, P=0.034). Overweight CPP subjects showed higher insulin 
resistance than normal weight CPP subjects. Insulin resistance was not significantly 
different between overweight and normal weight non-CPP subjects. VFT was 
not significantly different between CPP and non-CPP subjects (2.22±0.79 cm vs. 
2.74±1.47 cm, P=0.169). However, overweight and obese CPP subjects (body mass 
index percentile>85%) had lower VFT than non-CPP obese subjects.
Conclusion: Central obesity, defined using ultrasonography-measured VFT, might 
be associated with early pubertal development in Korean girls. However, VFT was 
not higher in CPP than non-CPP patients and was not significantly correlated with 
insulin resistance. Further longitudinal studies with a larger cohort are needed.
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Childhood obesity has become a major public health issue, and the numbers of obese 
children and adolescents continue to increase.1) Obesity is now recognized as a disease because 
growing evidence has revealed its associations with various metabolic complications.2) In 
addition, excess adiposity is known to influence multiple aspects of pubertal development, 
such as the timing of pubertal initiation and pubertal hormonal parameters.3) However, the 
relationships between these factors remain somewhat inconsistent. 
Previous studies have suggested that differences in adiposity distribution may exert 
different effects on metabolic complications. For example, central obesity is associated with 
visceral fat accumulation and is more commonly associated with impaired glucose and lipid 
metabolism, compared to subcutaneous fat accumulation.4) In addition, even among nonobese 
individuals, visceral fat accumulation is correlated with glucose intolerance, dyslipidemia, 
and hypertension.5) However, few studies have evaluated the association between pubertal 
development and visceral fat accumulation. Thus, the present study evaluated visceral 
adiposity among Korean girls with early pubertal development, and its associations with their 
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metabolic and hormonal parameters, in order to understand 
the relationship between sexual maturation and obesity in the 
context of precocious puberty.
Materials and methods
1. Study population and design
We retrospectively analyzed data from 128 girls who were 
<8 years old and had visited the Yonsei University Gangnam 
Severance Hospital between October 2013 and November 
2016 for evaluation of early breast development (objective 
breast budding that exceeded Tanner stage II). The subjects had 
undergone sonographic measurement of visceral fat thickness 
(VFT) and subcutaneous fat thickness (SFT). We also reviewed 
their gonadotropin-releasing hormone (GnRH) stimulation 
test results and defined central precocious puberty (CPP) as 
peak luteinizing hormone (LH) concentrations of ≥5 IU/L and 
non-CPP as peak LH concentrations of <5 IU/L. We excluded 
patients who underwent testing under nonfasting condition, 
had underlying diseases that might interrupt normal pubertal 
development, or had incomplete hormone test results. A total 
of 54 patients were included in the CPP group and 18 patients 
were included in the non-CPP group. This study's protocol was 
approved by the Institutional Review Board of Yonsei University 
Gangnam Severance Hospital (approval number: 3-2017-0178).
2. VFT and SFT measurements
Ultrasonography was performed to measure VFT and SFT 
using a high-resolution ultrasonographic system (SA 9900, 
Medison, Seoul, Korea). VFT was defined as the fat tissue 
thickness between the linea alba and the aorta, while SFT was 
defined as the fat tissue thickness between the skin-fat interface 
and the linea alba.6) Transverse scanning was performed to 
measure the maximum VFT and SFT using 3.5 MHz and 7.5 
MHz probes, respectively. Both parameters were measured at 1 
cm above the umbilicus by the same pediatric radiologist. 
3. Clinical and laboratory data
Height and weight were measured without shoes but with 
light clothing, and the measurements were rounded up to 
nearest 0.1 cm and 0.1 kg. We calculated the standard deviation 
scores for height, weight, and body mass index (BMI) based 
on the 2007 Korean National Growth Charts.7) Patients with 
BMI percentiles above the 85th percentile were labeled as 
being overweight, and patients with BMI percentiles below the 
85th percentile were labeled as having normal weight. Breast 
development was assessed by a single pediatric endocrinologist 
through visual inspection and palpation, and Tanner staging was 
used to grade pubertal stage (ranging from grade I [prepubertal] 
to grade V [adult]).8) 
 Blood samples had been taken to analyze lipid profiles, 
serum glucose, insulin, insulin resistance index, and baseline 
sex hormones (LH [IU/L], estradiol [pg/mL], sex hormone-
binding globulin, free estradiol index, and insulin-like growth 
factor 1 [IGF-1]). The homeostasis model assessment-insulin 
resistance (HOMA-IR) score was used as an indicator of insulin 
resistance, and was calculated as (fasting plasma insulin×fasting 
plasma glucose)/405.9) Bone age was assessed using radiography 
of the left hand. The patients' provided blood samples that were 
obtained at 0, 30, 60, 90, and 120 minutes after an injection of 
GnRH (100 μg of Relefact, Sanofi-Aventis, Paris, France), and 
their levels of LH were subsequently measured.10) A peak LH 
level of 5 IU/L was used as the cutoff for identifying a pubertal 
response.10)
4. Statistical analysis
All data were analyzed using IBM SPSS Statistics ver. 23.0 
(IBM Co., Armonk, NY, USA). Associations between continuous 
variables were evaluated using Pearson correlation coefficient. 
Intergroup comparisons of nonparametric data sets were 
Table 1. Comparison of anthropometric data, biochemical data, 
visceral fat thickness, and subcutaneous fat thickness between 
central precocious puberty and non-CPP group
Characteristic CPP (n=54) Non-CPP (n=18) P-value
CA (yr) 8.27±0.63 8.29±0.61 0.896
BA (yr) 9.95±0.99 9.62±0.87 0.213
BA–CA (yr) 1.67±0.83 1.32±0.66 0.102
Height SDS 1.07±0.86 1.07±0.94 0.993
Weight SDS 0.71±0.78 1.18±0.99 0.040
BMI SDS 0.27±0.90 1.00±1.17 0.008
Baseline LH (IU/L) 1.27±1.47 0.58±0.89 0.023
Peak LH (IU/L) 18.87±14.56 3.19±1.13 <0.001
Estradiol (pg/mL) 16.78±21.12 8.06±7.78 0.001
SHBG (nmol/L) 89.82±37.45 69.08±45.32 0.058
DHEA-S (μg/dL) 49.93±34.45 46.02±29 0.683
FEI 21.40±27.6 17.96±21.48 0.498
Insulin (mU/L) 26.63±23.81 29.45±33.69 0.745
IGF-1 (ng/mL) 310.15±109.01 231.88±51.03 <0.001
HOMA-IR 6.61±5.98 9.23±17.23 0.337
Cholesterol (mg/dL) 165.39±28.32 168.33±29.20 0.706
HDL (mg/dL) 53.09±9.11 50.78±11.53 0.386
LDL (mg/dL) 89.16±23.56 98.16±26.95 0.181
Triglycerides (mg/dL) 115.68±53.12 97.0±53.25 0.201
VFT(cm) 2.22±0.79 2.74±1.47 0.169
SFT(cm) 1.18±0.98 1.33±0.60 0.554
VFT:SFT 2.32±1.20 2.31±1.27 0.979
Values are presented as mean±standard deviation.
CPP, central precocious puberty; CA, chronological age; BA, bone 
age; SDS, standard deviation score; BMI, body mass index; LH, 
luteinizing hormone; SHBG, sexual hormone binding globulin; 
DHEA-S, dehydroepiandrosterone sulfate; FEI, free estradiol index; 
IGF-1, insulin-line growth factor 1; HOMA-IR, homeostatic model 
assessment-insulin resistance; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; VFT, visceral fat thickness; SFT, 
subcutaneous fat thickness.
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performed using the Kruskal-Wallis test. Multiple regression 
analysis was used to verify the associations between VFT, 
SFT, BMI, and age at the onset of thelarche. Differences were 
considered statistically significant at a P-value of <0.05. 
Results
1. Baseline characteristics
The baseline characteristics of the CPP and non-CPP groups 
are shown in Table 1. Among the 72 patients, 54 patients (75%) 
were CPP and 18 patients (25%) were non-CPP. Compared to 
the CPP group, the non-CPP group had significantly higher 
weight SDS (0.71±0.78 vs. 1.18±0.09, P=0.04) and BMI SDS 
(0.27±0.90 vs. 1.00±1.17, P=0.008). The CPP group had 
significantly higher baseline levels of LH (1.27±1.47 IU/L vs. 
0.58±0.89 IU/L, P=0.023), estradiol (16.78±21.12 pg/mL vs. 
8.06±7.78 pg/mL, P=0.001), and IGF-1 (310.15±109.01 ng/mL 
vs. 231.88±51.03 ng/mL, P<0.001). There were no significant 
differences between the two groups in their values for VFT 
(2.22±0.79 cm vs. 2.74±1.47 cm, P=0.169) and SFT (1.18±0.98 
cm vs. 1.33±0.60 cm, P=0.554).
2. Comparing the CPP and non-CPP groups based on 
    BMI percentiles
The patients in the CPP and non-CPP groups were also 
categorized into overweight and normal weight groups. 
The overweight patients in the CPP group exhibited trends 
towards higher values for the difference between bone age 
and chronological age, baseline LH, peak LH, estradiol, free 
estradiol index, insulin, IGF-1, and HOMA-IR (Table 2, Fig. 1). 
Furthermore, overweight CPP group exhibited higher HOMA-
IR and IGF-1 compared normal weight CPP subjects; however, 
non-CPP subjects did not show significant difference of 











































































Fig. 1. VFT, IGF-1, HOMA-IR, and estradiol level among CPP and non-CPP groups categorized by BMI percentage. 
Values are presented as median. (A) Significant difference (P=0.016) was shown between overweight CPP and 
overweight non-CPP groups. (B) Significant difference (P<0.001) was shown between overweight CPP and 
overweight non-CPP groups. (C) Significant difference (P=0.013) was shown between overweight CPP and non-
overweight CPP groups. (D) Significant difference (P=0.033) was shown between overweight CPP and overweight 
non-CPP groups. VFT, visceral fat thickness; IGF-1, insulin-like growth factor-1; BMI, body mass index; HOMA-IR, 
homeostatic model assessment-insulin resistance; CPP, central precocious puberty.
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groups. Moreover, compared to the normal weight CPP group, 
the overweight CPP group exhibited nonsignificantly higher 
values for baseline and peak LH (Table 2). No differences were 
observed when we compared the overweight and normal weight 
patients in the non-CPP group.
The overweight patients in the CPP and non-CPP groups 
exhibited trends towards higher VFT and SFT values, compared 
to their normal weight counterparts. Overweight patients in 
the non-CPP group had significantly higher VFT, compared 
to overweight patients in the CPP group (3.3 cm vs. 2.45 cm, 
P<0.05). No significant differences were observed when we 
compared normal weight patients in the CPP and non-CPP 
groups (Table 2).
3. Relationship between age onset of thelarche and 
    adiposity parameters
Table 3 shows the Pearson correlation coefficients for 
the relationships between age at the onset of thelarche and 
multiple adiposity parameters. Age at the onset of thelarche was 
negatively correlated with VFT (r=-0.307, P<0.05) and SFT (r=-
0.255, P<0.05). In addition, BMI SDS was negatively but non-
significantly correlated with age at the onset of thelarche (r=-
0.107, P=0.373). In the multiple linear regression analysis, only 
VFT was independently associated with age at the onset of 
thelarche (β=-0.310, P<0.05) (Table 4). 
Table 2. Comparison of multiple factors between CPP and non-CPP group after categorizing into overweight and nonoverweight group 
according to BMI percentage
Characteristic
BMI≤85% BMI>85% Overall
P-valueNon-CPP (n=10) CPP (n=43) P-value Non-CPP (n=8) CPP (n=11) P-value
CA (yr) 8.5 (0.7) 8.4 (0.7) 0.204 8.3 (1.7) 8.7 (0.7) 0.351 0.441
BA (yr) 9.5 (1.0) 9.5 (1.0) 0.479 9.5 (2.0) 11.0 (1.0) 0.075 0.075
BA–CA* 1.0 (1.1) 1.3 (1.1) 0.138 1.4 (1.2) 2.5 (1.0) 0.062 0.023
Weight SDS*,† 0.61 (0.82) 0.48 (0.75) 0.828 2.13 (1.04) 1.76 (0.95) 0.923 <0.001
BMI SDS*,† 0.59 (1.44) 0.07 (0.63) 0.469 2.05 (0.97) 1.67 (0.69) 0.579 <0.001
Baseline LH (IU/L)† 0.1 (0.2) 0.6 (1.2) <0.001 0.6 (0.5) 0.8 (1.1) 0.778 0.001
Peak LH (IU/L) 3.2 (2.3) 10.3 (19.7) <0.001 2.6 (2.3) 19.1 (22.4) <0.001 0.001
Estradiol (pg/mL) 5.5 (7.3) 5.0 (20.4) 0.620 4.0 (0.1) 9.65 (42.1) 0.033 0.039
SHBG (nmol/L)*,† 77.3 (73.1) 94.0 (48.9) 0.585 44.5 (21.5) 52.25 (19.5) 0.026 0.001
FEI† 7.0 (12.0) 6.37 (15.1) 0.682 12.13 (25.0) 24.63 (60.5) 0.788 0.033
Insulin (mU/L) 20.0 (24.4) 15.3 (31.3) 0.856 19.7 (52.3) 46.9 (47.5) 0.600 0.057
IGF-1 (ng/mL)* 245 (75.0) 268 (169.0) 0.119 235 (89.0) 422 (111.0) <0.001 0.001
HOMA-IR* 4.64 (6.49) 3.79 (8.4) 0.838 4.95 (10.5) 12.2 (10.9) 0.545 0.048
VFT (cm)† 2.1 (1.2) 2.2 (0.9) 0.964 3.3 (1.1) 2.45 (0.9) 0.016 0.011
SFT (cm)† 0.8 (1.0) 0.9 (0.4) 0.991 1.9 (0.9) 1.53 (0.9) 0.152 0.001
VFT:SFT 2.62 (2.37) 2.18 (1.36) 0.964 2.0 (1.3) 1.82 (2.0) 0.778 0.876
Values are presented as median (interquartile range). Comparative analysis between groups was done with the Kruskal-Wallis test. 
CPP, central precocious puberty; CA, chronologic age; BA, bone age; SDS, standard deviation score; BMI, body mass index; LH, luteinizing 
hormone; SHBG, sex hormone binding globulin; FEI, free estradiol index; IGF-1, insulin-like growth factor-1; HOMA-IR, homeostatic model 
assessment-insulin resistance; VFT, visceral fat thickness; SFT, subcutaneous fat thickness.
*P<0.05, significant difference between non-overweight and overweight CPP groups. †P<0.05, significant difference between 
nonoverweight and overweight non-CPP group.
Table 3. Pearson correlation coefficients of multiple factors to 
age at thelarche
Parameter
Age at onset of thelarche (n=72)
r P-value
VFT (cm) -0.307 0.009
SFT (cm) -0.255 0.031
BMI SDS -0.107 0.373
Insulin (mU/L) 0.070 0.558
HOMA-IR 0.099 0.407
Triglyceride (mg/dL) -0.028 0.814
Cholesterol (mg/dL) -0.022 0.855
HDL (mg/dL) 0.119 0.319
LDL (mg/dL) -0.060 0.615
VFT, visceral fat thickness; SFT, subcutaneous fat thickness; BMI, 
body mass index; SDS, standard deviation score; HOMA-IR, 
homeostatic model assessment-insulin resistance; HDL, high-
density lipoprotein; LDL, low-density lipoprotein.
Table 4. Multiple regression analysis of factors explaining the 
age onset at thelarche
Parameter
Age at thelarche (n=72)
Beta (β) SE (β) P-value VIF
VFT (cm) -0.310 -0.188 0.019 1.320
SFT (cm) -0.220 -0.151 0.074 1.159
BMI SDS 0.123 0.074 0.362 1.418
R2 of model=0.138.
SE, standard error; VFT, visceral fat thickness; SFT, subcutaneous 
fat thickness; BMI, body mass index standard score deviation; 
SDS, standard deviation score.
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Discussion
Previous studies regarding obesity and pubertal development 
have demonstrated that greater BMI is associated with an 
increased likelihood of  early pubertal development.11-13) 
However, the effect of fat distribution on pubertal development 
remains unclear. Although there is an overlap between central 
obesity measures and BMI-based obesity, measuring BMI does 
not provide useful information regarding fat distribution.14) 
Pattern of fat distribution, rather than obesity, has been reported 
as a more important factor for predicting metabolic and 
cardiovascular morbidity and multiple methods have been used 
for assessment.15) By far, computed tomography is the most 
accurate tool, but the risk of radiation exposure and relatively 
high cost limits its routine use in clinics.16) Other methods such 
as skinfold thickness, waist circumference, waist-hip ratio are 
also commonly used clinical tool for assessing pattern of fat 
distribution. However, each of those methods is known for their 
own limitations. Skinfold thickness has its limitation associated 
with the caliper method and may pose difficulty in severely 
obese subjects.15) Waist circumference and waist-hip ratio are 
widely used in adults, but shows inconsistent correlation with 
visceral fat in children.15,17) In contrast, ultrasound has shown to 
be a reliable, convenient, and reproducible method for assessing 
fat distribution according to previous studies in children.15,16,18) 
Also, in girls with early puberty, ultrasonograhic evaluation 
offers additional benefit of examining uterus and ovary in 
evaluating the cause of early puberty. Therefore, we used 
ultrasound for assessing the central obesity of girls with early 
puberty. 
Previous studies have attempted to clarify the effects of 
central obesity on pubertal maturation, as Chen et al.19) 
found that increased central obesity, based on the waist-to-
height ratio, was associated with earlier breast development in 
children aged 6–12 years. Mechanisms underlying the process 
involves insulin resistance, hyperinsulinemia, and leptin.20) 
Insulin resistance caused by obesity leads to compensatory 
hyperinsulinemia which subsequently causes decrease in sex 
hormone binding globulin and increased estrogen level.20) Also, 
increased aromatization from excess adipose tissue results in 
increased estrogen level.21) Moreover, increased leptin causes 
central activation of GnRH and gonadotropin secretion and 
direct stimulation of LH and FSH release.22,23) However, leptin 
alone may not be sufficient to initiate puberty, as Ahmed et 
al.24) reported that leptin administration did not consistently 
advance puberty. Furthermore, Roemmich et al.25) proposed 
that insulin resistance may contribute to pubertal maturation by 
interfering with leptin signaling, which could cause additional 
weight gain and accelerated pubertal growth. Thus, to our 
current knowledge obesity seems to have influence on pubertal 
maturation. 
In the present study of  72 girls, ultrasonographically 
measured VFT showed good correlation with BMI (r=0.485). 
Furthermore, VFT was positively correlated with earlier 
thelarche onset, indicating that subjects with increased VFT had 
earlier onset age of breast development. We further speculated 
that increasing trend of VFT would be shown as pubertal 
changes progress; however, our results have shown non-CPP 
groups having thicker VFT than CPP groups, although not 
statistically significant. The reason for such result is not clear 
to us, but it can be explained by the fact that non-CPP group 
had significantly higher BMI SDS compared to CPP subjects 
(1.00±1.17 vs. 0.27±0.90, P=0.008). Considering the normal 
physiologic weight gain during pubertal changes and earlier 
studies that have found CPP patients having higher BMI 
compared to early puberty patients,26) our conflicting finding to 
previous research may be due to small sample size which may 
have created a sampling bias. Another possible explanation is 
the effect of serum sex steroid concentrations that might have 
affected on body fat distribution. Puberty normally begins 
with gonadotropin-driven ovarian estrogen production and 
estrogen levels progressively increases as the hypothalamic-
pituitary-gonadal axis matures. The amount of visceral fat is 
thought to be modulated by the balance between estrogens and 
androgens, and estrogens may contribute to decreasing visceral 
fat accumulation by downregulating androgen receptors.27) 
In our study, CPP group had significantly higher estradiol 
compared to non-CPP group, and high levels of estradiol in 
CPP group may have had influence on lower VFT compared to 
non-CPP group. De Ridder et al.’s cross-sectional data stating 
the high estrogen concentrations among early pubertal girls 
correlating with lesser central fat verifies with our findings.28) 
Moreover, pubertal increases in sex steroid secretions can 
stimulate growth hormone (GH) secretion, which protects 
against increased visceral adiposity, as Roemmich et al.29) and 
Björntorp30) found that GH treatment selectively reduces the 
abdominal visceral fat of children with GH deficiency. Likewise, 
CPP group in our study had significantly higher IGF-1 level 
compared to non-CPP group, and the profoundly increased 
IGF-1 may have had a role in protecting against gaining 
visceral fat in CPP group. As pubertal maturation induces more 
distinctive changes in hormones such as estradiol and IGF-1, 
it is speculated that visceral fat gain may slow down due to the 
hormonal effects. However, many other factors such as ethnicity, 
genetic background, degree of physical activity, and metabolic 
factors can affect visceral adiposity. Therefore, research with 
larger sample is needed to examine the influence of changing 
sex hormone concentrations on visceral adiposity. 
In regard to metabolic parameters of the study subjects, 
we revealed that overweight CPP subjects had the highest 
insulin resistance among the 4 groups (normal weight CPP, 
normal weight non-CPP, overweight CPP, and overweight 
non-CPP). Previous cross-sectional and longitudinal studies 
have reported that pubertal changes are related to increased 
insulin resistance.31) Moran et al.31) in their cross-sectional 
study, stated that insulin resistance was highest in Tanner 
stages III and IV, and it return to normal level as approaching 
Tanner stage V. Also, in a longitudinal study by Ball et al.,32) 
similar result was found, demonstrating the increased insulin 
resistance in midpuberty and recovery in the end of puberty. 
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Furthermore, overweight children are more prone to insulin 
resistance than normal weight children, and several studies have 
stated that obese children do not recover insulin sensitivity 
at the end of puberty.33) In our study, overweight CPP group 
showed distinctively higher insulin resistance even compared 
to overweight non-CPP group. Such finding verifies the 
physiologic increase in insulin resistance during puberty and 
negative effect of obesity in insulin resistance in children with 
CPP. 
Insulin resistance during pubertal maturation seems to be a 
physiologic change. Mechanisms underlying such phenomenon 
mainly involves GH and IGF-1 which is normally increased 
during puberty.34) Children who are treated with recombinant 
GH for idiopathic short stature showed transient insulin 
resistance during the course of treatment.35) It is hypothesized 
that GH is associated with changes of phosphoinositide-3 
kinase, the rate limiting enzyme in the metabolic insulin 
signaling pathway.36) Thus, pubertal increase in GH is possible 
cause of insulin resistance in CPP groups. Independently of 
puberty, obesity itself is known for having negative impact 
on insulin resistance by the complex mechanisms involving 
leptin, inflammatory cytokines, and free fatty acids produced 
by adipocytes.37) Thus, obese children during pubertal change 
are more insulin-resistant than lean children, as verified by our 
study's result. 
There are several limitations and subjects for future improve-
ments in this study. First of all, present study's retrospective 
design and small sample size (54 patients with CPP and 18 
patients with non-CPP) can be associated with risks of selection 
bias. Also, subjects in non-CPP group whose peak LH level was 
near 5 IU/L may have a significant overlap with CPP group. 
Therefore, stratifying the result of LHRH stimulation test and 
comparing the groups of profoundly low and high peak LH 
result may provide more significant result; however, we were 
not able to do such analysis due to limited number of samples. 
Moreover, the present study did not consider some factors that 
may influence puberty and obesity, such as physical activity, 
nutritional status, and leptin level in biochemical analysis. 
Finally, the present study evaluated only the patients with 
pubertal changes. For clearer results, ultrasound measurement 
of central obesity, metabolic profiles, and hormonal parameters 
of prepubertal children for comparison of pubertal children 
is required. Nevertheless, this study has found usefulness of 
ultrasound measurement of VFT and its correlation with early 
breast development of girls. Future studies should include 
large study samples through longitudinal study with additional 
associated factors regarding precocious puberty.
In conclusion, among girls with early breast development, 
ultrasonographically measured VFT was a useful index of 
central obesity. Also, increased VFT was associated with early 
breast development in girls. However, VFT was not higher in 
subjects with CPP than non-CPP, and was not significantly 
correlated with insulin resistance. Multiple mechanisms 
may be involved in the association of central obesity with 
hormonal changes in the pubertal state. Therefore, further 
large, longitudinal studies of children throughout their pubertal 
transition or children with precocious puberty throughout the 
courses of treatment are needed to clarify the relationship.
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